[Anesthetic management by continuous total intravenous anesthesia]. 1998

M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
Department of Anesthesiology, Osaka Medical College, Takatsuki.

Total intravenous anesthesia (TIVA) is one of the most recommended methods of anesthesia for the prevention of air pollution. But the intermittent administration of anesthetic agents has a disadvantage of elongating emergence time. When inexperienced residents undertake TIVA with larger doses of drugs to stabilize vital signs, it takes long emergence time. Therefore, we suggested a continuous TIVA with propofol, ketamine and vecuronium in combination with butorphanol (PKBt) or buprenorphine (PKBp). In this study, we compared emergence times in the subjects, who underwent general anesthesia with PKBt and PKBp. After induction with propofol (2 mg.kg-1), ketamine (0.5 mg.kg-1), vecuronium (0.1 mg.kg-1) and agonist-antagonist opioids, subjects in each group were maintained with continuous intravenous injection of propofol (2-10 mg.kg-1.h-1), ketamine (240 micrograms.kg-1.h-1) and vecuronium (80 micrograms.kg-1.h-1) in combination with butorphanol (8 micrograms.kg-1.h-1) or buprenorphine (0.4 microgram.kg-1.h-1). The emergence times were designated as Op time (the end of operation to awareness), Pr time (the end of propofol to awareness), and B time (the end of butorphanol or buprenorphine to awareness). The emergence times of Op, Pr and B were not different between the groups. The elderly patients showed longer B time than the younger. The patients with long anesthetic time showed longer B time than the patients with short anesthesia. The patients with general anesthesia combined with epidural anesthesia showed longer B time than the patients with only general anesthesia. But there were no differences in Op time and Pr time. We conclude that the continuous TIVA is useful to reduce emergence time and prevent air pollution.

UI MeSH Term Description Entries
D007649 Ketamine A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone,CI-581,Calipsol,Calypsol,Kalipsol,Ketalar,Ketamine Hydrochloride,Ketanest,Ketaset,CI 581,CI581
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D002077 Butorphanol A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain. 17-(Cyclobutylmethyl)morphinan-3,14-diol,Apo-Butorphanol,BC-2627,Beforal,Butorphanol Tartrate,Dolorex,Moradol,Stadol,Stadol NS,Torbugesic,BC 2627,BC2627
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
February 2005, Masui. The Japanese journal of anesthesiology,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
June 2015, Journal of cardiothoracic and vascular anesthesia,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
October 2006, Masui. The Japanese journal of anesthesiology,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
January 2015, Paediatric anaesthesia,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
January 2009, Journal of anesthesia,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
June 1991, Masui. The Japanese journal of anesthesiology,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
September 1990, Masui. The Japanese journal of anesthesiology,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
October 2022, Korean journal of anesthesiology,
M Onaka, and H Yamamoto, and M Akatsuka, and H Mori
December 2010, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!